Ionis Pharmaceuticals Resultados de beneficios anteriores

Pasado controles de criterios 0/6

Los beneficios de Ionis Pharmaceuticals han disminuido a una tasa media anual de -52.3%, mientras que en la industria Biotechs los beneficios crecieron en un 12.7% anualmente. Los ingresos han ido disminuyendo a una tasa media de 4.4% al año.

Información clave

-49.8%

Tasa de crecimiento de los beneficios

-49.7%

Tasa de crecimiento del BPA

Crecimiento de la industria Biotechs	17.0%
Tasa de crecimiento de los ingresos	-5.6%
Rentabilidad financiera	-129.8%
Margen neto	-49.5%
Última actualización de beneficios	31 Mar 2024

Actualizaciones de resultados anteriores recientes

Recent updates

Analysts Have Made A Financial Statement On Ionis Pharmaceuticals, Inc.'s (NASDAQ:IONS) First-Quarter Report

May 09

Lacklustre Performance Is Driving Ionis Pharmaceuticals, Inc.'s (NASDAQ:IONS) Low P/S

Apr 14

Is Ionis Pharmaceuticals (NASDAQ:IONS) Using Debt Sensibly?

Mar 18

Ionis Pharmaceuticals 2023 Earnings Review: Short-Term Pain, Long-Term Gain

Feb 23

Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) Investors Are Less Pessimistic Than Expected

Dec 28

Some Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) Analysts Just Made A Major Cut To Next Year's Estimates

Feb 25

Desglose de ingresos y gastos

Cómo gana y gasta dinero Ionis Pharmaceuticals. Basado en los últimos beneficios reportados, en base a los últimos doce meses (LTM).

Historial de beneficios e ingresos

NasdaqGS:IONS Ingresos, gastos y beneficios (USD Millions)
Fecha	Ingresos	Beneficios	Gastos G+A
31 Mar 24	777	-385	220
31 Dec 23	788	-366	213
30 Sep 23	615	-409	210
30 Jun 23	631	-309	174
31 Mar 23	576	-329	162
31 Dec 22	587	-270	150
30 Sep 22	875	7	141
30 Jun 22	849	-28	137
31 Mar 22	841	-4	148
31 Dec 21	810	-29	186
30 Sep 21	661	-608	207
30 Jun 21	688	-550	245
31 Mar 21	708	-495	272
31 Dec 20	729	-444	354
30 Sep 20	933	94	299
30 Jun 20	940	145	290
31 Mar 20	959	169	293
31 Dec 19	1,123	281	287
30 Sep 19	821	433	269
30 Jun 19	799	402	278
31 Mar 19	752	366	269
31 Dec 18	600	277	245
30 Sep 18	575	-41	224
30 Jun 18	548	-38	182
31 Mar 18	543	9	138
31 Dec 17	514	19	108
30 Sep 17	507	42	81
30 Jun 17	499	52	64
31 Mar 17	426	-15	52
31 Dec 16	373	-60	49
30 Sep 16	238	-184	44
30 Jun 16	176	-227	42
31 Mar 16	258	-134	40
31 Dec 15	284	-88	37
30 Sep 15	317	14	31
30 Jun 15	312	23	27
31 Mar 15	249	-24	23
31 Dec 14	214	-39	20
30 Sep 14	172	-94	18
30 Jun 14	151	-92	17
31 Mar 14	132	-90	16
31 Dec 13	147	-61	15
30 Sep 13	125	-39	13
30 Jun 13	113	-52	10

Ingresos de calidad: IONS actualmente no es rentable.

Margen de beneficios creciente: IONS actualmente no es rentable.

Análisis del flujo de caja libre vs. Beneficios

Análisis del crecimiento de los beneficios en el pasado

Tendencia de beneficios: IONS no es rentable, y las pérdidas han aumentado en los últimos 5 años a un ritmo de 52.3% al año.

Acelerando crecimiento: No se puede comparar el crecimiento de los beneficios de IONS en el último año con su promedio de 5 años, ya que actualmente no es rentable.

Beneficios vs. Industria: IONS no es rentable, por lo que resulta difícil comparar el crecimiento de sus beneficios en el último año con el de la industria Biotechs (-8.9%).

Rentabilidad financiera

Alta ROE: IONS tiene una rentabilidad financiera negativa (-94.72%), ya que actualmente no es rentable.

Ionis Pharmaceuticals Resultados de beneficios anteriores

Pasado controles de criterios 0/6

Información clave

Actualizaciones de resultados anteriores recientes

First quarter 2024 earnings: EPS exceeds analyst expectations while revenues lag behind

Full year 2023 earnings: EPS and revenues exceed analyst expectations

Third quarter 2023 earnings: EPS in line with analyst expectations despite revenue beat

Second quarter 2023 earnings: EPS and revenues exceed analyst expectations

Ionis Pharmaceuticals, Inc. to Report Q2, 2023 Results on Aug 09, 2023

First quarter 2023 earnings: EPS and revenues exceed analyst expectations

Recent updates

Biogen and Ionis Announce Topline Phase 1/2 Study Results of Investigational Drug in Amyotrophic Lateral Sclerosis

Lead Independent Director exercised options to buy US$612k worth of stock.

Analysts Have Made A Financial Statement On Ionis Pharmaceuticals, Inc.'s (NASDAQ:IONS) First-Quarter Report

Ionis Pharmaceuticals, Inc. Reaffirms Financial Guidance for the Year 2024

First quarter 2024 earnings: EPS exceeds analyst expectations while revenues lag behind

Ionis Pharmaceuticals, Inc., Annual General Meeting, Jun 06, 2024

Lacklustre Performance Is Driving Ionis Pharmaceuticals, Inc.'s (NASDAQ:IONS) Low P/S

Ionis Presents Positive Results from Phase 3 Balance Study of Olezarsen for Familial Chylomicronemia Syndrome

Is Ionis Pharmaceuticals (NASDAQ:IONS) Using Debt Sensibly?

Ionis Pharmaceuticals, Inc. Announces Positive Results from Phase 2 Study of ION224

Ionis Pharmaceuticals, Inc. Announces Executive Changes

Ionis Pharmaceuticals 2023 Earnings Review: Short-Term Pain, Long-Term Gain

Full year 2023 earnings: EPS and revenues exceed analyst expectations

Ionis Pharmaceuticals, Inc. Provides Earnings Guidance for the Year 2024

Ionis Pharmaceuticals, Inc. Announces U.S. Food and Drug Administration Grants Orphan Drug Designation to the Investigational Medicine Olezarsen for the Treatment of FCS

Founder recently sold US$1.2m worth of stock

Ionis Pharmaceuticals, Inc. Announces Positive Topline Results from Phase 3 Oasis-Hae Study of Investigational Donidalorsen in Patients with Hereditary Angioedema

Founder notifies of intention to sell stock

Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) Investors Are Less Pessimistic Than Expected

Founder notifies of intention to sell stock

Ionis Pharmaceuticals, Inc. Announces U.S. Food and Drug Administration Approves Ionis and AstraZeneca's WAINUA

Insider notifies of intention to sell stock

Ionis Pharmaceuticals, Inc. Appoints Michael Yang as a Member of Board

Ionis Pharmaceuticals (NASDAQ:IONS) Has Debt But No Earnings; Should You Worry?

A Look At The Intrinsic Value Of Ionis Pharmaceuticals, Inc. (NASDAQ:IONS)

Ionis Pharmaceuticals, Inc. Shares Positive Clinical Update from Ongoing Trial of Ion582 for Angelman Syndrome

Ionis Presents Positive Two-Year Results from the Phase 2 Open-Label Extension Study of Donidalorsen in Patients with Hereditary Angioedema

Ionis Pharmaceuticals, Inc. Provides Earnings Guidance for the Year 2023

Third quarter 2023 earnings: EPS in line with analyst expectations despite revenue beat

Senior Strategic Advisor & Director notifies of intention to sell stock

Ionis Pharmaceuticals, Inc. Announces Positive Olezarsen Topline Results from Phase 3 Study in People with Facilitate Chylomicronemia Syndrome

Second quarter 2023 earnings: EPS and revenues exceed analyst expectations

Ionis Pharmaceuticals (NASDAQ:IONS) Has Debt But No Earnings; Should You Worry?

Ionis Completes Enrollment in Phase 3 Cardio-TTRansform Study in Patients with TTR-Mediated Amyloid Cardiomyopathy

Ionis Pharmaceuticals, Inc. to Report Q2, 2023 Results on Aug 09, 2023

Ionis Pharmaceuticals, Inc. Announces Positive Topline, 85-Week Data from the Phase 3 Neuro-Ttransform Study in Patients with Hereditary Transthyretin-Mediated Amyloid Polyneuropathy

Founder notifies of intention to sell stock

Ionis Pharmaceuticals, Inc. Announces New Data Highlight Potential Benefit of SPINRAZA® (nusinersen) in Infants and Toddlers with Unmet Medical Needs After Gene Therapy

Ionis Pharmaceuticals, Inc. Announces Positive Donidalorsen Late-Stage Clinical Progress in HAE

Founder notifies of intention to sell stock

Is Ionis Pharmaceuticals (NASDAQ:IONS) Using Debt Sensibly?

First quarter 2023 earnings: EPS and revenues exceed analyst expectations

Price target decreased by 7.2% to US$47.48

Full year 2022 earnings: EPS exceeds analyst expectations

Founder recently sold US$1.0m worth of stock

Ionis Pharmaceuticals, Inc. Announces GSK Has Advanced Bepirovirsen into Phase 3 Development

Ionis Receives FDA Fast Track Designation for Olezarsen in Patients with Familial Chylomicronemia Syndrome

Founder exercised options and sold US$990k worth of stock

Does Ionis Pharmaceuticals (NASDAQ:IONS) Have A Healthy Balance Sheet?

Ionis Pharmaceuticals, Inc. Announces European Medicines Agency Accepts Marketing Authorization Application of Tofersen to Treat Rare, Genetic Form of ALS

Consensus forecasts updated

Insufficient new directors

Third quarter 2022 earnings: EPS and revenues exceed analyst expectations

Ionis Pharmaceuticals, Inc. Provides Revenue Guidance for the Full Year 2022

Ionis Pharmaceuticals, Inc. Announces Positive Data from GSK's Phase 2b Clinical Study of Bepirovirsen

Ionis Pharmaceuticals, Inc. Presents Positive Phase 2 Data in Patients with IgA Nephropathy At American Society of Nephrology's Kidney Week 2022

Ionis Pharmaceuticals, Inc. Announces Positive Results from Fesomersen Development Program

Oxford Properties Group, Inc. acquired 18.4-Acre Life Science Campus and Corporate Headquarters of Ionis Pharmaceutical in San Diego from Ionis Pharmaceuticals, Inc. (NasdaqGS:IONS).

Ionis Pharmaceuticals Looks Good For The Long Term

Ionis plans for new manufacturing site in California to support pipeline

Ionis Pharmaceuticals, Inc. Provides Update on Development Program Evaluating PCSK9 Antisense Medicine for the Treatment of Hypercholesterolemia

Ionis Pharmaceuticals, Inc. Presents Positive Results from Phase 3 Neuro-Ttransform Study At International Symposium on Amyloidosis

Ionis: 2 Drug Advancements With Potential Firsts

Second quarter 2022 earnings: EPS and revenues miss analyst expectations

Ionis Pharmaceuticals, Inc. Provides Earnings Guidance for the Year 2022

Ionis Pharmaceuticals Q2 2022 Earnings Preview

Ionis Pharmaceuticals (NASDAQ:IONS) Could Easily Take On More Debt

Insufficient new directors

Ionis Pharmaceuticals, Inc. Announces Positive Topline Results from Phase 2B Clinical Study of Fesomersen